NASDAQ:AVBP ArriVent BioPharma Q4 2025 Earnings Report $27.47 -0.47 (-1.68%) Closing price 04:00 PM EasternExtended Trading$27.46 -0.01 (-0.04%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ArriVent BioPharma EPS ResultsActual EPS-$0.78Consensus EPS -$0.87Beat/MissBeat by +$0.09One Year Ago EPSN/AArriVent BioPharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArriVent BioPharma Announcement DetailsQuarterQ4 2025Date3/5/2026TimeBefore Market OpensConference Call DateThursday, March 5, 2026Conference Call Time9:30AM ETUpcoming EarningsArriVent BioPharma's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) ArriVent BioPharma Earnings HeadlinesArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 19, 2026 | americanbankingnews.comLifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)May 18, 2026 | theglobeandmail.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 27 at 1:00 AM | Paradigm Press (Ad)ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull CaseMay 16, 2026 | seekingalpha.comCitigroup Cuts ArriVent BioPharma (NASDAQ:AVBP) Price Target to $43.00May 16, 2026 | americanbankingnews.comAVBP Share News TodayMay 15, 2026 | uk.investing.comSee More ArriVent BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ArriVent BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ArriVent BioPharma and other key companies, straight to your email. Email Address About ArriVent BioPharmaArriVent BioPharma (NASDAQ:AVBP) operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.View ArriVent BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Abercrombie Rallies as Strong Q1 Earnings Extend Winning StreakZscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityRecord Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy?Micron’s $1 Trillion Memory Melt-UpKeysight: The AI and Defense Stock Seeing Big Price Target BoostsAutoZone's Pullback Sets Up a Long-Term Buying OpportunityAST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Upcoming Earnings Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026)Dell Technologies (5/28/2026)Royal Bank Of Canada (5/28/2026)Toronto Dominion Bank (5/28/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
